The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
N. M. Reddy
No relevant relationships to disclose
R. Simmons
No relevant relationships to disclose
M. Caldwell
No relevant relationships to disclose
M. H. Jagasia
No relevant relationships to disclose
D. S. Morgan
No relevant relationships to disclose
S. I. Park
No relevant relationships to disclose
J. P. Greer
No relevant relationships to disclose
K. L. Richards
No relevant relationships to disclose